Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Mustang Bio, Inc.

MBIO

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.385 – $0.408
Volume 7,674
Market cap $3M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.96M
Price / earnings
—
Price / book
0.45×
Price / sales
—
EV / sales
—
EV / EBITDA
2.86×

Profitability

Earnings per share
-$0.47
Return on assets
-24.03%
Return on equity
-53.58%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.85×
Quick ratio
1.85×
Cash ratio
1.8×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$4.57M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MBIO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$850K$946K$880K$987K$957K$787K$1.22M-$223K
Research and development$208K$224K$178K-$317K-$333K$98K-$964K$197K
Total operating expenses$1.06M$1.17M$1.06M$670K$624K$885K$253K$1.02M
Operating income-$1.06M-$1.17M-$1.06M-$670K-$624K-$885K-$253K-$1.02M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$964K-$1.07M-$955K-$538K-$468K-$762K-$153K-$952K
Income taxes$0$0$0$0$0$0$0$0
Net income-$964K-$1.07M-$955K-$538K-$468K-$762K-$153K-$952K
Net income attributable to common shareholders-$964K-$1.07M-$955K-$538K-$468K-$762K-$153K-$952K
EBITDA-$1.06M-$1.17M-$1.06M-$670K-$624K-$885K-$219K$77K
Basic earnings per share-$0.14-$0.16-$0.14-$0.08-$0.07-$0.19-$0.05-$0.90
Diluted earnings per share-$0.14-$0.16-$0.14-$0.08-$0.07-$0.19-$0.05-$0.90

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand

The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.

GlobeNewswire Inc.

Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio, a clinical-stage biopharmaceutical company, announced the closing of a public offering of common stock and warrants, raising approximately $8 million. The company plans to use the proceeds for working capital and general corporate purposes.

GlobeNewswire Inc.

Mustang Bio Announces Pricing of $8 Million Public Offering

Mustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of common stock, Series C-1 warrants, and Series C-2 warrants, raising approximately $8 million in gross proceeds.

Investing.com

Fortress Biotech CEO buys $36.7k in preferred stock - Investing.com

Fortress Biotech CEO Dr. Lindsay A. Rosenwald has increased his stake in the company by purchasing $36.7k worth of Series A Cumulative Perpetual Preferred Stock. This move demonstrates the CEO's confidence in the company's future prospects.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 16, 20251-for-50reverse split
Apr 4, 20231-for-15reverse split